When On-Time is Late: Expediting US and Foreign Issuance
Sponsored by: McNeill Baur PLLC
Eyal Barash is a patent attorney who focuses his practice on life sciences. After receiving bachelor’s degrees in chemistry and history from Indiana University, he studied solid-state NMR spectroscopy at UC-Berkeley where he obtained a master’s degree in physical chemistry. After obtaining a law degree at Northwestern, he practiced law in Washington, DC for the world’s largest patent-law firm for 8 years before returning to his native town of West Lafayette. Back home, he was in-house counsel for various start-ups with successful exits culminating in the sale of Endocyte, where he was chief IP counsel, to Novartis in 2018 for $2.1B.
Eyal currently maintains a practice representing a variety of companies including start-ups from Purdue, MIT, and UC-San Francisco as well as publicly traded life science companies and nonprofits. For his clients, Eyal manages IP portfolios, negotiates complex transactions (including license agreements), and advises how to create valuable patent estates.
Amelia Feulner Baur, PhD, is a founding partner at McNeill Baur PLLC who specializes in the life sciences. She focuses her practice on strategic patent counseling, prosecution, and due diligence investigations, including pre-litigation portfolio reviews, and M&A and BD-related transactions. Amelia is a regular speaker and author on patent law topics including AIA post-grant proceedings, USPTO’s Subject Matter Eligibility, and patent prosecution. Amelia has received many awards and honors, including being named a 2023 Top 250 Women in IP by Managing Intellectual Property and a 2023 IAM Patent 1000 Recommended Individual. Amelia earned her PhD in Molecular Biology from The University of Texas Southwestern Medical Center at Dallas where she gained extensive hands-on experience in the fields of microbiology, immunology, biochemistry, molecular biology, and infectious diseases.
Deborah Herzfeld is a partner at McNeill Baur PLLC. Deb’s practice focuses on client counseling and worldwide patent prosecution and portfolio management, with an emphasis on pharmaceutical life cycles. Deb has worked in all phases of intellectual property law, beginning her career pursuing both litigation and prosecution work. Her extensive client counseling experience includes pre-litigation portfolio and due diligence analyses, as well as freedom-to-operate, patentability, validity, and infringement opinion work. Deb has held numerous leadership positions in the Patent Trial and Appeal Board (PTAB) Bar Association, including her current position as a Board Member. While in law school at the University of Virginia School of Law, Deb gained patent prosecution and licensing experience as a student associate at the University of Virginia Patent Foundation and received the Charles J. Frankel Award in Health Law upon graduation.
Lulu Wang, PhD, is the vice president, head of intellectual property at Orna Therapeutics, a circular RNA biotechnology company building new treatments for cancers and genetic diseases. She leads the company’s global intellectual property strategy, leveraging over 10 years of experience building and defending pharmaceutical patent portfolios. Prior to joining Orna, Lulu was a patent litigator and prosecutor who represented innovative biotechnology and pharmaceutical companies, including AbbVie, Eli Lilly, and Novartis, in obtaining, defending, and challenging numerous patents. She also has extensive experience conducting patent due diligences for multimillion and multibillion dollar deals, including acquisitions and partnerships. Lulu earned her BA in biology from Harvard College, PhD in neurobiology from Harvard Medical School, and JD from Harvard Law School. She currently chairs the Patent Legislation Committee of the American Bar Association and previously chaired its Chemical and Life Sciences Patents Committee.
